@article {MAGALH{\~A}ES1117, author = {TOM{\'A}S RODRIGUES MAGALH{\~A}ES and J{\'E}R{\^O}ME BENO{\^I}T and SLAVOM{\'I}RA N{\'E}{\v C}OV{\'A} and SUSAN NORTH and FELISBINA LU{\'I}SA QUEIROGA}, title = {Outcome After Radiation Therapy in Canine Intracranial Meningiomas or Gliomas}, volume = {35}, number = {2}, pages = {1117--1123}, year = {2021}, doi = {10.21873/invivo.12357}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To characterize a group of dogs diagnosed with meningioma or glioma treated with radiation therapy and assess the clinical impact of diagnosis and radiation protocol on survival time. Patients and Methods: Canine patient records from a single veterinary referral hospital, between 2011 and 2015, were searched for intracranial tumour cases treated with radiation therapy, as a sole modality. Thirty-two dogs were included. Results: Median survival times were 524 days [95\% confidence interval (CI)=287-677] in total, 512 days (95\% CI=101-682) for the glioma group and 536 days (95\% CI=249-677) for the meningioma group. No significant difference in survival was detected when using a definitive or a palliative protocol (p=0.130), nor other prognostic factors were found. Conclusion: Our results highlight the efficacy of radiation therapy in the treatment of canine meningioma, as well as glioma, suggesting a change in the current perception of the response of glial tumours to radiation.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/35/2/1117}, eprint = {https://iv.iiarjournals.org/content/35/2/1117.full.pdf}, journal = {In Vivo} }